GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pila Pharma AB (OSTO:PILA) » Definitions » Notes Receivable

Pila Pharma AB (OSTO:PILA) Notes Receivable : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pila Pharma AB Notes Receivable?

Pila Pharma AB's Notes Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Pila Pharma AB Notes Receivable Historical Data

The historical data trend for Pila Pharma AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pila Pharma AB Notes Receivable Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Pila Pharma AB Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pila Pharma AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Pila Pharma AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Pila Pharma AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pila Pharma AB Business Description

Traded in Other Exchanges
Address
Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

Pila Pharma AB Headlines

No Headlines